Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Ghiringhelli

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
The Oncologist|August 4, 2009
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?Caroline Robert, Francois Ghiringhelli
Future Oncology (London, England)|April 9, 2013
Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategiesFrancois Ghiringhelli, Lionel Apetoh
Nature Immunology|June 8, 2021
ILC2s in cancer: context mattersMelanie Bruchard, Francois Ghiringhelli
Oncotarget|December 20, 2018
Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancerFrancois Ghiringhelli, Caroline Truntzer
Frontiers in Immunology|April 27, 2019
Deciphering the Roles of Innate Lymphoid Cells in CancerMelanie Bruchard, Francois Ghiringhelli
Biomedical Journal|August 29, 2014
Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectivesFrancois Ghiringhelli, Lionel Apetoh
Oncoimmunology|September 20, 2023
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancerMarion Thibaudin, Francois Ghiringhelli
Anticancer Research|November 17, 2012
Metronomic cyclophosphamide with cisplatin and bevacizumab: a new chemotherapeutic regimen for refractory anaplastic ependymomaVeronique Lorgis, Olivier Varbedian, Francois Ghiringhelli
World Journal of Gastroenterology|February 23, 2013
Degarelix as a new antiangiogenic agent for metastatic colon cancer?Francois Ghiringhelli, Nicolas Isambert, Sylvain Ladoire
Cancers|June 2, 2021
Targeting BRAF and RAS in Colorectal CancerHelene Bellio, Jean David Fumet, Francois Ghiringhelli
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
The Oncologist|August 4, 2009
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?Caroline Robert, Francois Ghiringhelli
Future Oncology (London, England)|April 9, 2013
Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategiesFrancois Ghiringhelli, Lionel Apetoh
Nature Immunology|June 8, 2021
ILC2s in cancer: context mattersMelanie Bruchard, Francois Ghiringhelli
Oncotarget|December 20, 2018
Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancerFrancois Ghiringhelli, Caroline Truntzer
Frontiers in Immunology|April 27, 2019
Deciphering the Roles of Innate Lymphoid Cells in CancerMelanie Bruchard, Francois Ghiringhelli
Biomedical Journal|August 29, 2014
Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectivesFrancois Ghiringhelli, Lionel Apetoh
Oncoimmunology|September 20, 2023
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancerMarion Thibaudin, Francois Ghiringhelli
Anticancer Research|November 17, 2012
Metronomic cyclophosphamide with cisplatin and bevacizumab: a new chemotherapeutic regimen for refractory anaplastic ependymomaVeronique Lorgis, Olivier Varbedian, Francois Ghiringhelli
World Journal of Gastroenterology|February 23, 2013
Degarelix as a new antiangiogenic agent for metastatic colon cancer?Francois Ghiringhelli, Nicolas Isambert, Sylvain Ladoire
Cancers|June 2, 2021
Targeting BRAF and RAS in Colorectal CancerHelene Bellio, Jean David Fumet, Francois Ghiringhelli
Pageof 10